In our article Indacaterol for COPD (DTB 2011; 50: 58–60) we included the statement: “This recommends a short-acting inhaled bronchodilator (either a beta₂ agonist or short-acting muscarinic antagonist) as initial therapy for the relief of breathlessness and for reducing exercise limitation, with the addition of long-acting bronchodilators and/or an inhaled corticosteroid for people who remain breathless or have exacerbations.” Thank you to commentators who pointed out that it should have read “with the addition of long-acting bronchodilators and an inhaled corticosteroid for people who remain breathless or have exacerbations.”1